Table of Contents Author Guidelines Submit a Manuscript
Parkinson’s Disease
Volume 2015 (2015), Article ID 973298, 5 pages
http://dx.doi.org/10.1155/2015/973298
Research Article

Association of a BACE1 Gene Polymorphism with Parkinson’s Disease in a Norwegian Population

1The Norwegian Centre for Movement Disorders, Stavanger University Hospital, 4011 Stavanger, Norway
2Centre for Organelle Research, University of Stavanger, 4036 Stavanger, Norway
3Department of Biological Sciences, St. John’s University, New York, NY 11439, USA
4Department of Neurology, Haukeland University Hospital, 5021 Bergen, Norway
5Institute for Clinical Medicine, University of Bergen, 5021 Bergen, Norway
6Department of Neurology, Stavanger University Hospital, 4011 Stavanger, Norway

Received 5 October 2015; Accepted 29 November 2015

Academic Editor: Antonio Pisani

Copyright © 2015 Johannes Lange et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. J. Jankovic, “Parkinson's disease: clinical features and diagnosis,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 79, no. 4, pp. 368–376, 2008. View at Publisher · View at Google Scholar · View at Scopus
  2. P. Svenningsson, E. Westman, C. Ballard, and D. Aarsland, “Cognitive impairment in patients with Parkinson's disease: diagnosis, biomarkers, and treatment,” The Lancet Neurology, vol. 11, no. 8, pp. 697–707, 2012. View at Publisher · View at Google Scholar · View at Scopus
  3. S. N. Gomperts, J. J. Locascio, D. Rentz et al., “Amyloid is linked to cognitive decline in patients with Parkinson disease without dementia,” Neurology, vol. 80, no. 1, pp. 85–91, 2013. View at Publisher · View at Google Scholar · View at Scopus
  4. G. Halliday, M. Hely, W. Reid, and J. Morris, “The progression of pathology in longitudinally followed patients with Parkinson's disease,” Acta Neuropathologica, vol. 115, no. 4, pp. 409–415, 2008. View at Publisher · View at Google Scholar · View at Scopus
  5. H. Zheng and E. H. Koo, “The amyloid precursor protein: beyond amyloid,” Molecular Neurodegeneration, vol. 1, article 5, 2006. View at Publisher · View at Google Scholar · View at Scopus
  6. H. Lv, L. Jia, and J. Jia, “Promoter polymorphisms which modulate APP expression may increase susceptibility to Alzheimer's disease,” Neurobiology of Aging, vol. 29, no. 2, pp. 194–202, 2008. View at Publisher · View at Google Scholar · View at Scopus
  7. C. M. Kirschling, H. Kölsch, C. Frahnert, M. L. Rao, W. Maier, and R. Heun, “Polymorphism in the BACE gene influences the risk for Alzheimer's disease,” NeuroReport, vol. 14, no. 9, pp. 1243–1246, 2003. View at Publisher · View at Google Scholar · View at Scopus
  8. J. Clarimón, J. Bertranpetit, F. Calafell, M. Boada, L. Tàrraga, and D. Comas, “Association study between Alzheimer's disease and genes involved in Aβ biosynthesis, aggregation and degradation: suggestive results with BACE1,” Journal of Neurology, vol. 250, no. 8, pp. 956–961, 2003. View at Publisher · View at Google Scholar · View at Scopus
  9. M. Kim, J. Suh, D. Romano et al., “Potential late-onset Alzheimer's disease-associated mutations in the ADAM10 gene attenuate α-secretase activity,” Human Molecular Genetics, vol. 18, no. 20, pp. 3987–3996, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. D. Scheuner, C. Eckman, M. Jensen et al., “Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease,” Nature Medicine, vol. 2, no. 8, pp. 864–870, 1996. View at Publisher · View at Google Scholar · View at Scopus
  11. L. M. Bekris, N. M. Galloway, S. Millard et al., “Amyloid precursor protein (APP) processing genes and cerebrospinal fluid APP cleavage product levels in Alzheimer's disease,” Neurobiology of Aging, vol. 32, no. 3, pp. 556,e13–556.e23, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. G. Alves, B. Müller, K. Herlofson et al., “Incidence of Parkinson's disease in Norway: the Norwegian ParkWest study,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 80, no. 8, pp. 851–857, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. M. Emre, D. Aarsland, R. Brown et al., “Clinical diagnostic criteria for dementia associated with Parkinson's disease,” Movement Disorders, vol. 22, no. 12, pp. 1689–1837, 2007. View at Publisher · View at Google Scholar
  14. G. Alves, J. Lange, K. Blennow et al., “CSF Abeta42 predicts early-onset dementia in Parkinson disease,” Neurology, vol. 82, no. 20, pp. 1784–1790, 2014. View at Publisher · View at Google Scholar · View at Scopus
  15. L. Myllykangas, F. Wavrant-De Vrièze, T. Polvikoski et al., “Chromosome 21 BACE2 haplotype associates with Alzheimer's disease: a two-stage study,” Journal of the Neurological Sciences, vol. 236, no. 1-2, pp. 17–24, 2005. View at Publisher · View at Google Scholar · View at Scopus
  16. M. M. Carrasquillo, O. Belbin, T. A. Hunter et al., “Replication of CLU, CR1, and PICALM associations with Alzheimer disease,” Archives of Neurology, vol. 67, no. 8, pp. 961–964, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. E. M. Reiman, K. Chen, X. Liu et al., “Fibrillar amyloid-beta burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease,” Proceedings of the National Academy of Sciences of the United States of America, vol. 106, no. 16, pp. 6820–6825, 2009. View at Publisher · View at Google Scholar · View at Scopus
  18. Q. Jiang, C. Y. D. Lee, S. Mandrekar et al., “ApoE promotes the proteolytic degradation of Abeta,” Neuron, vol. 58, no. 5, pp. 681–693, 2008. View at Publisher · View at Google Scholar · View at Scopus
  19. J. Gao, X. Huang, Y. Park et al., “Apolipoprotein E genotypes and the risk of Parkinson disease,” Neurobiology of Aging, vol. 32, no. 11, pp. 2106.e1–2106.e6, 2011. View at Publisher · View at Google Scholar · View at Scopus
  20. X. Solé, E. Guinó, J. Valls, R. Iniesta, and V. Moreno, “SNPStats: a web tool for the analysis of association studies,” Bioinformatics, vol. 22, no. 15, pp. 1928–1929, 2006. View at Publisher · View at Google Scholar · View at Scopus
  21. P. Nowotny, J. M. Kwon, S. Chakraverty, V. Nowotny, J. C. Morris, and A. M. Goate, “Association studies using novel polymorphisms in BACE1 and BACE2,” NeuroReport, vol. 12, no. 9, pp. 1799–1802, 2001. View at Publisher · View at Google Scholar · View at Scopus
  22. S. A. Jo, K. Ahn, E. Kim et al., “Association of BACE1 gene polymorphism with Alzheimer's disease in Asian populations: meta-analysis including Korean samples,” Dementia and Geriatric Cognitive Disorders, vol. 25, no. 2, pp. 165–169, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. A. Patel, S. D. Rees, M. A. Kelly et al., “Association of variants within APOE, SORL1, RUNX1, BACE1 and ALDH18A1 with dementia in Alzheimer's disease in subjects with Down syndrome,” Neuroscience Letters, vol. 487, no. 2, pp. 144–148, 2011. View at Publisher · View at Google Scholar · View at Scopus
  24. L. Cai, G. Tang, L. Chen, B. Zhang, S. Jiang, and D. Ren, “Genetic studies of A2M and BACE1 genes in Chinese Han Alzheimer's disease patients,” NeuroReport, vol. 16, no. 9, pp. 1023–1026, 2005. View at Publisher · View at Google Scholar · View at Scopus
  25. J. Shi, S. Zhang, M. Tang et al., “The 1239G/C polymorphism in exon 5 of BACE1 gene may be associated with sporadic Alzheimer's disease in Chinese Hans,” American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, vol. 124, no. 1, pp. 54–57, 2004. View at Google Scholar · View at Scopus
  26. R. Vassar, B. D. Bennett, S. Babu-Khan et al., “β-Secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE,” Science, vol. 286, no. 5440, pp. 735–741, 1999. View at Publisher · View at Google Scholar · View at Scopus
  27. M. K. Beyer, G. Alves, K. S. Hwang et al., “Cerebrospinal fluid Aβ levels correlate with structural brain changes in Parkinson's disease,” Movement Disorders, vol. 28, no. 3, pp. 302–310, 2013. View at Publisher · View at Google Scholar
  28. G. Alves, K. F. Pedersen, B. R. Bloem et al., “Cerebrospinal fluid amyloid-β and phenotypic heterogeneity in de novo Parkinson's disease,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 84, no. 5, pp. 537–543, 2013. View at Publisher · View at Google Scholar · View at Scopus
  29. J.-H. Kang, D. J. Irwin, A. S. Chen-Plotkin et al., “Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau 181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease,” JAMA Neurology, vol. 70, no. 10, pp. 1277–1287, 2013. View at Publisher · View at Google Scholar · View at Scopus
  30. C.-H. Lin and R.-M. Wu, “Biomarkers of cognitive decline in Parkinson's disease,” Parkinsonism & Related Disorders, vol. 21, no. 5, pp. 431–443, 2015. View at Publisher · View at Google Scholar
  31. S. J. Chung, Y. Jung, M. Hong et al., “Alzheimer's disease and Parkinson's disease genome-wide association study top hits and risk of Parkinson's disease in Korean population,” Neurobiology of Aging, vol. 34, no. 11, pp. 2695.e1–2695.e7, 2013. View at Google Scholar · View at Scopus
  32. V. Moskvina, D. Harold, G. C. Russo et al., “Analysis of genome-wide association studies of Alzheimer disease and of Parkinson disease to determine if these 2 diseases share a common genetic risk,” JAMA Neurology, vol. 70, no. 10, pp. 1268–1276, 2013. View at Publisher · View at Google Scholar · View at Scopus
  33. C. Wider, C. Vilariño-Güell, B. Jasinska-Myga et al., “Association of the MAPT locus with Parkinson's disease,” European Journal of Neurology, vol. 17, no. 3, pp. 483–486, 2010. View at Publisher · View at Google Scholar · View at Scopus
  34. C. Wider, O. A. Ross, K. Nishioka et al., “An evaluation of the impact of MAPT, SNCA and APOE on the burden of Alzheimer's and Lewy body pathology,” Journal of Neurology, Neurosurgery and Psychiatry, vol. 83, no. 4, pp. 424–429, 2012. View at Publisher · View at Google Scholar · View at Scopus
  35. V. Leduc and J. Poirier, “Polymorphisms at the paraoxonase 1 L55M and Q192R loci affect the pathophysiology of Alzheimer's disease: emphasis on the cholinergic system and beta-amyloid levels,” Neurodegenerative Diseases, vol. 5, no. 3-4, pp. 225–227, 2008. View at Publisher · View at Google Scholar · View at Scopus
  36. A. C. Belin, C. Ran, A. Anvret et al., “Association of a protective paraoxonase 1 (PON1) polymorphism in Parkinson's disease,” Neuroscience Letters, vol. 522, no. 1, pp. 30–35, 2012. View at Publisher · View at Google Scholar · View at Scopus
  37. B. A. Benitez and C. Cruchaga, “TREM2 and neurodegenerative disease,” The New England Journal of Medicine, vol. 369, no. 16, pp. 1567–1568, 2013. View at Publisher · View at Google Scholar · View at Scopus
  38. O. Calero, M. J. Bullido, J. Clarimón et al., “A common BACE1 polymorphism is a risk factor for sporadic Creutzfeldt-Jakob disease,” PLoS ONE, vol. 7, no. 8, Article ID e43926, 2012. View at Publisher · View at Google Scholar · View at Scopus
  39. L. M. Bekris, D. W. Tsuang, E. R. Peskind et al., “Cerebrospinal fluid Aβ42 levels and APP processing pathway genes in Parkinson's disease,” Mov Disord, vol. 30, no. 7, pp. 936–944, 2015. View at Publisher · View at Google Scholar